8-K: Imunon Reports Positive Phase 2 Ovarian Cancer Trial Results and Secures $10 Million in Funding

Imunon announced positive topline results from its Phase 2 OVATION 2 study for advanced ovarian cancer, showing a significant increase in overall survival, and secured $10 million in a registered direct offering.

Summary

• Imunon reported its second quarter 2024 financial results and provided a business update, highlighting positive topline results from the Phase 2 OVATION 2 study of IMNN-001 in advanced ovarian cancer.
• The study showed an 11.1-month increase in median overall survival (OS) for patients treated with IMNN-001 plus standard-of-care compared to standard-of-care alone.
• A subset of patients who received at least 20% of specified treatments per protocol experienced a 15.7-month increase in median OS.
• For patients treated with a PARP inhibitor, the hazard ratio decreased to 0.41, with median OS in the IMNN-001 arm not yet reached compared to 37.1 months in the standard-of-care arm.
• The company also reported a three-month improvement in progression-free survival (PFS) with a hazard ratio of 0.79.
• Imunon plans to hold an End-of-Phase 2 meeting with the FDA to discuss the protocol for a Phase 3 study, anticipated to begin in the first quarter of 2025.
• The company also announced the first participants were vaccinated in the Phase 1 clinical trial of its COVID-19 booster vaccine, IMNN-101, with topline data expected by year-end 2024.
• Imunon secured $10 million in gross proceeds through a registered direct offering of 5,000,000 shares at $2.00 per share.
• The company reported a net loss of $4.8 million, or $0.51 per share, for the second quarter of 2024, compared to a net loss of $5.6 million, or $0.61 per share, for the same period in 2023.
• Imunon had $5.3 million in cash, investments, and accrued interest receivable as of June 30, 2024, and believes it has sufficient capital to fund operations into the third quarter of 2025.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results and a successful capital raise, indicating strong potential for the company's future. The financial results are mixed, but the overall tone is optimistic.

Positives

• The OVATION 2 study demonstrated a significant increase in overall survival for patients treated with IMNN-001.
• The company successfully raised $10 million in a registered direct offering, strengthening its financial position.
• The Phase 1 clinical trial for the COVID-19 booster vaccine has commenced, with topline data expected by year-end 2024.
• The company has established internal capability to produce plasmid DNA, reducing CMC costs.
• The company believes it has sufficient capital to fund operations into the third quarter of 2025.

Negatives

• The company reported a net loss of $4.8 million for the second quarter of 2024.
• The company had $5.3 million in cash, investments and accrued interest receivable as of June 30, 2024.
• Research and development expenses were $2.8 million in the second quarter of 2024.

Risks

• The company's future success depends on the outcome of clinical trials and regulatory approvals.
• There are risks and uncertainties associated with forward-looking statements, including unforeseen changes in research and development activities.
• The company may need to raise additional capital in the future to fund its operations.

Future Outlook

The company anticipates beginning a Phase 3 study of IMNN-001 in the first quarter of 2025 and expects topline data from the IMNN-101 Phase 1 study by year-end 2024. They believe they have sufficient capital to fund operations into the third quarter of 2025.

Management Comments

• Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON, stated that the positive topline results from the Phase 2 OVATION 2 Study were the culmination of years of dedication by the IMUNON team.
• Dr. Lindborg believes the results provide hope to women suffering from ovarian cancer.
• Dr. Lindborg noted that the $9.3 million in net proceeds from a capital raise, along with capital conservation efforts, allows the company to report important catalysts, including the initiation of a planned Phase 3 study of IMNN-001.

Industry Context

The positive results from the OVATION 2 study are significant in the immuno-oncology space, particularly for advanced ovarian cancer, which has a poor prognosis. The development of a COVID-19 booster vaccine also aligns with ongoing efforts to combat the pandemic. The company's focus on DNA-based therapies is a differentiating approach from conventional therapies.

Comparison to Industry Standards

• The 11.1-month increase in median overall survival in the OVATION 2 study is a notable improvement compared to standard-of-care for advanced ovarian cancer, where median survival is often less than 2 years.
• The hazard ratio of 0.74 in the ITT population and 0.64 in the per-protocol population indicate a significant improvement in survival compared to standard treatments.
• The results are comparable to or better than some other immunotherapies in development for ovarian cancer, such as checkpoint inhibitors, which have shown varying degrees of efficacy.
• The company's approach of using DNA-based immunotherapy is different from traditional antibody-based therapies, and the results suggest a promising alternative.
• The company's ability to secure $10 million in funding in a challenging market is a positive sign of investor confidence in its technology and pipeline.

Stakeholder Impact

• Shareholders will likely react positively to the positive clinical trial results and the successful capital raise.
• Patients with advanced ovarian cancer may benefit from the potential approval of IMNN-001.
• Employees may be motivated by the company's progress and future prospects.
• The company's financial stability is improved by the recent capital raise, which may benefit suppliers and creditors.

Next Steps

• The company plans to hold an End-of-Phase 2 meeting with the FDA to discuss the protocol for a Phase 3 study.
• The company anticipates beginning a Phase 3 study of IMNN-001 in the first quarter of 2025.
• The company plans to present full OVATION 2 Study results at an upcoming medical conference and submit the results for publication in a peer-reviewed medical journal.
• The company expects topline data from the IMNN-101 Phase 1 study by year-end 2024.

Key Dates

Keywords

IMNN-001, ovarian cancer, immunotherapy, clinical trial, Phase 2, Phase 3, COVID-19 vaccine, IMNN-101, capital raise, FDA, PlaCCine, overall survival, progression-free survival